KIKA Medical, a pioneer of intelligence solutions designed to fully leverage the value of clinical studies, announces it has raised $10 million in Series B financing, led by NGN Capital.
Gérard Moufflet joins the company as Chief Executive Officer
Boston, MA.; Paris, France; October 19, 2005. KIKA Medical announces today that it has received a $10 million investment from funds advised by NGN Capital, and from Boston-based investment fund Shiprock Capital LLC. KIKA Medical is a worldwide provider of innovative intelligence solutions specifically designed to help the life sciences community to fully leverage the value of the most advanced clinical studies and reach new levels of business efficiency. A pioneer of the area, KIKA Medical has acquired a validated experience through more than 100 studies across 50 countries, especially in the cardiovascular field.
Combining advanced software technologies with experienced professional services, KIKA Medical delivers solutions to build, operate, store, track, analyze and document Clinical Studies, across all study phases, from Electronic Data Capture to Reports publication. The Eventa™ Suite is the only solution that can collect, unify and handle sophisticated information from various sources, e.g. medical imaging and vital signs, and include it into the electronic patient file, enabling sponsors to directly exploit the whole set of patients' data. Developed, maintained and permanently enhanced by KIKA, the Eventa Suite is fully compliant with FDA 21 CFR Part 11.
KIKA Medical also announces that Gérard Moufflet has joined KIKA Medical as Chief Executive Officer. G. Moufflet brings more than 30 years of experience in the life sciences industry, most notably as Managing Director at Advent International and a Corporate Vice President at Baxter International, where he spent 17 years. He will lead a seasoned team of business and scientific professionals with substantial experience in both the medical device and pharmaceutical clinical trial management, as well as in advanced software development. Frédéric Durand-Salmon, founder of the company will assume the role of Chief Technology Officer and sit on the Board of Directors.
"We believe that, well beyond simple EDC, there is an opportunity to provide top managements in the life science community with advanced intelligence tools, to reach fast, cost-effective and competitive decisions in a number of areas, e.g. product developments, regulatory compliance, marketing opportunities" says KIKA Medical CEO Gérard Moufflet. "We have the technology and the experience to meet these expectations. The new funding will help us move forward in this direction, with continued innovation, enhanced support and services capabilities, and a significantly increased presence on our key markets in the U.S.A. and in Europe."
KIKA Medical at a glance
KIKA Medical has been founded by Frédéric Durand-Salmon and a team of professionals with strong backgrounds in Clinical Studies, Medical Device and Medical Imaging, as well as in software technologies. Since 2000, the company is entirely focused on developing advanced web-based intelligence tools and services to meet the most demanding clinical studies needs.
KIKA Medical has developed the Eventa Suite, a powerful, yet flexible and intuitive software solution, easily adopted by clinicians and investigators. Thanks to unique features enabling interconnectivity with a majority of life support information systems, it can handle the broadest scope of clinical data and include it into the electronic patient file, enabling sponsors to directly exploit the whole set of patients' data, and making it a solution of choice for advanced studies run in high-tech environments (e.g; Cath Labs, Surgical Suites or Intensive Care Units).
Along with its software platform and tools, KIKA Medical brings a set of dedicated Professional Services, and a unique know-how to help clients engineer integrated workflows best adjusted to their needs. KIKA Medical's solutions provide all study stakeholders with real-time access to a wealth of clinical data, captured, integrated and interpreted much faster in a single seamless workflow. With enhanced data quality, reduced handling costs and decreased processing time, sponsors are fully in control of the process and can make competitive business decision to launch new products or improve existing products life cycles.
With operations in Europe and in the USA, KIKA Medical offers various ASP deployment options, all supported by a team of dedicated professionals.
KIKA Medical's Board of Directors include: Eric Archambeau, Silicon Valley repeat entrepreneur and private investor; Frédéric Durand-Salmon, company founder; William Gedale, Managing General Partner, NGN Capital; Gérard Moufflet, Chairman and CEO; Dr. Georg Nebgen, Managing General Partner, NGN Capital; Jean-Paul Ortelli, Partner at Acceleration International - who bring with them valuable software expertise and healthcare industry experience.
Six Beacon Street
Boston, MA 02108 - USA
Tel : 617 619 99 90
Fax : 617 557 31 36 |
35 rue de Rambouillet
75012 Paris - France
Tel : 01 53 17 95 70
Fax : 01 44 73 40 11
|
Contact
Laurence Clavère
lclavere@kikamedical.com
Tel + 33 6 72 38 05 38
About KIKA Medical
KIKA Medical is a worldwide provider of innovative intelligence solutions specifically designed to help the life sciences community to fully leverage the value of the most advanced clinical studies and reach new levels of business efficiency.
Combining advanced software technologies with experienced professional services, KIKA Medical delivers solutions to build, operate, store, track, analyze and document Clinical Studies, across all study phases, from Electronic Data Capture to Reports publication. Simple to deploy and used, they are easily adopted by all stakeholders. The Eventa™ Suite is the only solution that can collect, unify and handle sophisticated information from various sources, e.g. medical imaging and vital signs, and include it into the electronic patient file. With richer information, enhanced data quality, reduced handling costs and decreased processing time, sponsors are fully in control of the process and can make competitive business decision to launch new products or improve existing products life cycles.
KIKA Medical brings to its clients a validated experience, acquired through 100+ studies across 50 countries. It has operations in the US, headquartered in Boston, and in Europe, headquartered in Paris, France.
For more information, please visit www.kikamedical.com.
About NGN Capital
NGN Capital is an international diversified healthcare venture capital investment group with offices in New York, NY, Greenwich, CT, and Heidelberg, Germany. NGN Capital is comprised of a professional team and advisors with exceptional investment and management backgrounds in the Healthcare and Venture Capital industry from leading institutions on a global basis. NGN's professionals were directly involved in transformational developments in healthcare that led to significant realizations for investors. NGN's advisors are recognized experts in their respective fields of healthcare, science and corporate value creation and work actively with NGN's professionals. Collectively, NGN's professionals and advisors bring substantial value creation achievements and commercial expertise in healthcare ventures to the investments of NGN BioMed I and its portfolio companies.
NGN Capital's healthcare investments include Aerovance, Power Medical Interventions, EKOS, Santhera Pharmaceuticals, BioArray Solutions, and Jerini.
For more information, please visit www.ngncapital.com.